Literature DB >> 25344903

Bioinformatics for cancer immunotherapy target discovery.

Lars Rønn Olsen1, Benito Campos, Mike Stein Barnkob, Ole Winther, Vladimir Brusic, Mads Hald Andersen.   

Abstract

The mechanisms of immune response to cancer have been studied extensively and great effort has been invested into harnessing the therapeutic potential of the immune system. Immunotherapies have seen significant advances in the past 20 years, but the full potential of protective and therapeutic cancer immunotherapies has yet to be fulfilled. The insufficient efficacy of existing treatments can be attributed to a number of biological and technical issues. In this review, we detail the current limitations of immunotherapy target selection and design, and review computational methods to streamline therapy target discovery in a bioinformatics analysis pipeline. We describe specialized bioinformatics tools and databases for three main bottlenecks in immunotherapy target discovery: the cataloging of potentially antigenic proteins, the identification of potential HLA binders, and the selection epitopes and co-targets for single-epitope and multi-epitope strategies. We provide examples of application to the well-known tumor antigen HER2 and suggest bioinformatics methods to ameliorate therapy resistance and ensure efficient and lasting control of tumors.

Entities:  

Mesh:

Year:  2014        PMID: 25344903     DOI: 10.1007/s00262-014-1627-7

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  8 in total

1.  Improved peptide-MHC class II interaction prediction through integration of eluted ligand and peptide affinity data.

Authors:  Christian Garde; Sri H Ramarathinam; Emma C Jappe; Morten Nielsen; Jens V Kringelum; Thomas Trolle; Anthony W Purcell
Journal:  Immunogenetics       Date:  2019-06-10       Impact factor: 2.846

Review 2.  Peptide vaccines in cancer-old concept revisited.

Authors:  Takumi Kumai; Hiroya Kobayashi; Yasuaki Harabuchi; Esteban Celis
Journal:  Curr Opin Immunol       Date:  2016-12-09       Impact factor: 7.486

Review 3.  Current status and future directions of cancer immunotherapy.

Authors:  Hongming Zhang; Jibei Chen
Journal:  J Cancer       Date:  2018-04-19       Impact factor: 4.207

4.  Large-scale in-silico identification of a tumor-specific antigen pool for targeted immunotherapy in triple-negative breast cancer.

Authors:  Jessica Kaufmann; Nicolas Wentzensen; Titus J Brinker; Niels Grabe
Journal:  Oncotarget       Date:  2019-04-02

5.  Identification of prognosis-related alternative splicing events in kidney renal clear cell carcinoma.

Authors:  Yongdi Zuo; Liang Zhang; Weihao Tang; Wanxin Tang
Journal:  J Cell Mol Med       Date:  2019-09-05       Impact factor: 5.310

6.  Induction of Peptide-specific CTL Activity and Inhibition of Tumor Growth Following Immunization with Nanoparticles Coated with Tumor Peptide-MHC-I Complexes.

Authors:  Sang-Hyun Kim; Ha-Eun Park; Seong-Un Jeong; Jun-Hyeok Moon; Young-Ran Lee; Jeong-Ki Kim; Hyunseok Kong; Chan-Su Park; Chong-Kil Lee
Journal:  Immune Netw       Date:  2021-12-22       Impact factor: 6.303

Review 7.  Investigating the role of peptides in effective therapies against cancer.

Authors:  Reza Naeimi; Asrin Bahmani; Saeid Afshar
Journal:  Cancer Cell Int       Date:  2022-03-27       Impact factor: 5.722

8.  Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N.

Authors:  Jacquelyn Smith; Mark D Robida; Krista Acosta; Bharathi Vennapusa; Amita Mistry; Greg Martin; Alton Yates; H James Hnatyszyn
Journal:  Diagn Pathol       Date:  2016-05-18       Impact factor: 2.644

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.